Fluoroquinolone positioning in hospital antimicrobial stewardship programs

U.S. Pharmacist

Volumn 32, Issue 12, 2007, Pages

  Rapp, Robert P ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PREFERENCE; DRUG SAFETY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL CARE; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; QT PROLONGATION; RECOMMENDED DRUG DOSE; STREPTOCOCCUS PNEUMONIA; URINARY TRACT INFECTION;

EID: 48249128395     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (36)

1. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-177.
2. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000;283:749-755.
3. Marrie TJ. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia. Chemotherapy. 2004;50 (suppi 1):11-15.
4. Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Pharmacotherapy. 2001;21:89S-94S.
5. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother. 1999;43(suppl B):1-11.
6. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51:1019-1074.
7. Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther. 2000;22:798-817.
8. Yip C, Lee AJ. Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature. Clin Ther. 2006;28:1857-1866.
9. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63:2769-2802.
10. Karlowsky JA, Jones ME, Thornsberry C, et al. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis. 2005;40(suppl 2):S89-S98.
11. Karlowsky JA, Kelly U, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents. 2002;19:21-31.
12. Avelox (moxifloxacin hydrochloride) tablets; Avelox I.V. (moxifloxacin hydrochloride in sodium chloride injection. Bayer Pharmaceuticals Corp. June 2004.
13. Levaquin (Levofloxacin) [package insert]. Ortho-McNell Pharmaceutical; 2007.
14. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thorasic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
15. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol. 2001;1:459-463.
16. Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998-2002). Clin Infect Dis. 2003;36:963-970.
17. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - An update. Clin Infect Dis. 2004;39(suppl 3):S142-S150.
18. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62:13-59.
19. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis. 2005;41 (suppl 2):S120-S126.
20. Yang S, Clayton SR, Zechiedrich EL. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J Antimicrob Chemother. 2003;51:545-556.
21. Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis. 2003;45:63-67.
22. Bayer Pharmaceuticals Corp. Cipro (ciprofloxacin hydrochloride) tablets; Cipro (ciprofloxacin hydrochloride) oral suspension [prescribing information]. December, 2005.
23. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 2001;47:811-818.
24. Ebert SC. Application of pharmacokinetics and pharmacodynamics to antibiotic selection. P&T. 2004;29:244-250.
25. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119:1114-1122.
26. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Disease. 2004;189:1590-1597.
27. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2002;44:43-49.
28. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760.
29. Poole M, Anon J, Paglia M, et al. A trial of high-dose, short-course levofloxacin for the treatment of acute bacterial sinusitis. Otolaryngol Head Neck Surg. 2006;134:10-17.
30. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med. 2006;100:2129-2136.
31. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther. 2003;25:485-506.
32. Richard GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology. 1998;52:51-55.
33. Richard GA, Childs SJ, Fowler CL, et al. Safety and efficacy of levofloxacin versus ciprofloxacin in complicated urinary tract infections in adults. Pharm Ther. 1998;23:534-540.
34. Bundrick W, Heron SP, Ray P, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology. 2003;62:537-541.
35. Hoban DJ. Antibiotics and collateral damage. Clin Cornerstone. 2003;(suppl 3):S12-S20.
36. Kyne L, Hamel MB, Polavarm R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.